Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04165031 · OUTCOME

Phase 2: Progression-Free Survival (PFS) Non-Small Lung Cancer (NSCLC Cohorts)

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation · Source last updated 2021-11-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Baseline to Objective Progression or Death Due to Any Cause

What was measured

PFS was defined as the time from study enrollment (for non-randomized cohorts)/ the time from randomization (for randomized cohorts) to the first observation of progressive disease (PD) or death without documented disease progression per RECIST V1.1 criteria.

Analysis population: Zero participants were analyzed due to early termination of study.

Groups in this outcome

LY3499446 Monotherapy + Combination Drugs Phase 2

LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV).

Docetaxel Phase 2

Docetaxel IV infusion.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
LY3499446 Monotherapy + Combination Drugs Phase 20
Docetaxel Phase 20

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    units
    Participants
description
PFS was defined as the time from study enrollment (for non-randomized cohorts)/ the time from randomization (for randomized cohorts) to the first observation of progressive disease (PD) or death without documented disease progression per RECIST V1.1 criteria.
groups
  1. description
    LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV).
    id
    OG000
    title
    LY3499446 Monotherapy + Combination Drugs Phase 2
  2. description
    Docetaxel IV infusion.
    id
    OG001
    title
    Docetaxel Phase 2
population Description
Zero participants were analyzed due to early termination of study.
reporting Status
POSTED
time Frame
Baseline to Objective Progression or Death Due to Any Cause
title
Phase 2: Progression-Free Survival (PFS) Non-Small Lung Cancer (NSCLC Cohorts)
type
PRIMARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice